

## Ocrevus® (ocrelizumab) (Intravenous)

Document Number: OHSU HEALTHSERVICES-0298

Last Review Date: 12/02/2025

Date of Origin: 04/25/2017

Dates Reviewed: 04/2017, 9/19/2017, 12/2017, 03/2018, 06/2018, 10/2018, 09/2019, 10/2020, 10/2021, 10/2022, 10/2023, 12/2024, 12/2025

### I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 12 months.
- Renewal: Prior authorization validity may be renewed every 12 months thereafter.

### II. Dosing Limits

#### Max Units (per dose and over time) [HCPCS Unit]:

##### Initial dose:

- 300 billable units (300 mg) on day 1 and day 15

##### Subsequent doses:

- 600 billable units (600 mg) every 6 months

### III. Initial Approval Criteria <sup>1</sup>

Prior authorization validity is provided in the following conditions:

- Patient is at least 18 years of age; **AND**
- Patient has been screened for the presence of Hepatitis B virus (HBV) prior to initiating treatment **AND** does not have active disease (i.e., positive HBsAg and anti-HBV tests); **AND**
- Patient has had baseline serum immunoglobulins assessed; **AND**
- Patient does not have a history of life-threatening administration reactions to ocrelizumab; **AND**

#### Universal Criteria <sup>1</sup>

- Provider will confirm that patient will not receive live or live-attenuated vaccines while on therapy or within 4 weeks prior to initiation of treatment; **AND**
- Patient does not have an active infection; **AND**

- Patient will have serum aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), alkaline phosphatase, and bilirubin levels measured at baseline and periodically throughout therapy; **AND**
- Must be used as single agent therapy; **AND**
- Patient has not received a dose of ocrelizumab or ublituximab within the past 5 months; **AND**

**Multiple Sclerosis †<sup>1,7,11,16</sup>**

- Patient must have a confirmed diagnosis of multiple sclerosis (MS) as documented by laboratory report (i.e., MRI); **AND**
  - Patient has a diagnosis of a relapsing form of MS [i.e., relapsing-remitting MS (RRMS)\*, active secondary progressive disease (SPMS)\*\*, or clinically isolated syndrome (CIS)\*\*\*]; **AND**

- For relapsing MS: Patient must have had an inadequate response to an adequate trial of one of the following drugs: dimethyl fumarate, fingolimod, teriflunomide, or glatiramer acetate (generic, Glatopa), unless contraindicated or not tolerated; **OR**
  - Patient has a diagnosis of primary progressive MS (PPMS)\*; **AND**
    - Patient is less than 65 years of age; **AND**
    - Patient has an expanded disability status scale (EDSS) score of ≤ 6.5

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

**\*Definitive diagnosis of relapsing-remitting MS (RRMS) OR primary progressive MS (PPMS) is based upon<sup>16</sup>:**

- Dissemination in space (*see below*) **AND** one or more of the following:
  - Positive cerebrospinal fluid (CSF) (e.g., presence of oligoclonal bands or kappa free light chain index)
  - Positive central vein sign (CVS) (e.g., presence of six or more lesions with CVS; if fewer than 6 white matter lesions are seen on MRI, the number of CVS positive lesions should outnumber the CVS negative lesions)
  - Dissemination in time (DIT) (*see below*)
  - Presence of lesions in at least four of five CNS anatomical locations; **OR**
- Lesions present in one CNS site (including patients with 12 months or longer progression from onset) **AND** one or more of the following:
  - CSF positivity and CVS positivity
  - CSF positivity and paramagnetic rim lesion (PRL) positivity (e.g., presence of one or more PRL)
  - DIT (*see below*) and CVS positivity
  - DIT (*see below*) and PRL positivity

Unless contraindicated, MRI should be obtained (even if criteria are met).	
<u>Dissemination in space</u> <i>(Development of lesions in distinct anatomical locations within the CNS; multifocal)</i>	<u>Dissemination in time</u> <i>(Development/appearance of new CNS lesions over time)</i>
<ul style="list-style-type: none"> <li>MRI indicating typical lesions in ≥ 2 of 5 areas of the CNS (optic nerve, intracortical or juxtacortical, periventricular, infratentorial, or spinal cord); <b>OR</b></li> <li>In patients with progressive disease (patients with 12 months or longer progression from onset), two spinal cord lesions</li> </ul>	<ul style="list-style-type: none"> <li>≥2 clinical attacks; <b>OR</b></li> <li>Simultaneous presence of gadolinium enhancing and non-enhancing lesions at any time; <b>OR</b></li> <li>A new T2-hyperintense or gadolinium enhancing lesion on follow-up MRI</li> </ul>

**\*\*Active secondary progressive MS (SPMS) is defined as the following:** <sup>8,11-13,15</sup>

- Expanded Disability Status Scale (EDSS) score ≥ 3.0; **AND**
- Disease is progressive ≥ 3 months following an initial relapsing-remitting course (i.e., EDSS score increase by 1.0 in patients with EDSS ≤5.5 or increase by 0.5 in patients with EDSS ≥6); **AND**
  - ≥ 1 relapse within the previous 2 years; **OR**
  - Patient has gadolinium-enhancing activity OR new or unequivocally enlarging T2 contrast-enhancing lesions as evidenced by MRI

**\*\*\*Definitive diagnosis of CIS is based upon ALL of the following:** <sup>11</sup>

- A monophasic clinical episode with patient-reported symptoms and objective findings reflecting a focal or multifocal inflammatory demyelinating event in the CNS
- Neurologic symptom duration of at least 24 hours, with or without recovery
- Absence of fever or infection
- Patient is not known to have multiple sclerosis

#### IV. Renewal Criteria <sup>1,6,10,14</sup>

Prior authorization validity may be renewed based on the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe infusion reactions, severe infections, progressive multifocal leukoencephalopathy, malignancy, hypogammaglobulinemia, immune-mediated colitis, clinically significant liver injury, etc.; **AND**
- Continuous monitoring of response to therapy indicates a beneficial response\* [manifestations of MS disease activity include, but are not limited to, an increase in annualized relapse rate (ARR), development of new/worsening T2 hyperintensities or enhancing lesions on MRI, and progression of sustained impairment as evidenced by expanded disability status scale (EDSS), timed 25-foot walk (T25-FW), 9-hole peg test (9-HPT)]

**\*Note:**

- Inadequate response, in those who have been adherent and receiving therapy for sufficient time to realize the full treatment effect, is defined as  $\geq 1$  relapse,  $\geq 2$  unequivocally new MRI-detected lesions, or increased disability on examination over a one-year period.

**PPMS**

- Patient continues to be ambulatory, defined as an EDSS score of  $<7.5$

## V. Dosage/Administration <sup>1</sup>

Indication	Dose
Multiple Sclerosis	<p><u>Initial dose:</u> 300 mg intravenous infusion, followed two weeks later by a second 300 mg IV infusion</p> <p><u>Subsequent doses:</u> 600 mg IV infusion every 6 months</p> <ul style="list-style-type: none"> <li>• Administer first subsequent dose 6 months after infusion 1 of the initial dose</li> </ul>

## VI. Billing Code/Availability Information

HCPCS:

- J2350 – Injection, ocrelizumab, 1 mg; 1 billable unit = 1 mg

NDC:

- Ocrevus 300 mg/10 mL single-dose vial: 50242-0150-xx

## VII. References

1. Ocrevus [package Insert]. South San Francisco, CA; Genentech, Inc.; August 2025. Accessed November 2025.
2. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *N Engl J Med.* 2017 Jan 19;376(3):209-220.
3. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Engl J Med.* 2017 Jan 19;376(3):221-234.
4. Gawronski KM, Rainka MM, Patel MJ, Gengo FM. Treatment Options for Multiple Sclerosis: Current and Emerging Therapies. *Pharmacotherapy.* 2010; 30(9):916-927.
5. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology.* 2002 Jan 22; 58(2):169-78.

6. Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. *Can J Neurol Sci.* 2013 May;40(3):307-23.
7. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. *Ann Neurol.* 2011 Feb; 69(2): 292–302. doi: 10.1002/ana.22366.
8. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology.* 2014 Jul 15;83(3):278-86.
9. Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. <https://ms-coalition.org/the-use-of-disease-modifying-therapies-in-multiple-sclerosis-updated/>. Accessed November 2025.
10. Rae-Grant, A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology®* 2018;90:777-788. Reaffirmed: 2025 Oct 19.
11. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2.
12. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet.* 2018;391(10127):1263. Epub 2018 Mar 23.
13. Lorscheider J, Buzzard K, Jokubaitis V, et al, on behalf of the MSBase Study Group. Defining secondary progressive multiple sclerosis. *Brain*, Volume 139, Issue 9, September 2016, Pages 2395–2405, <https://doi.org/10.1093/brain/aww173>.
14. Freedman MS, Devonshire V, Duquette P, et al; Canadian MS Working Group. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. *Can J Neurol Sci.* 2020 Jul;47(4):437-455. doi: 10.1017/cjn.2020.66.
15. Cree BAC, Arnold DL, Chataway J, et al. Secondary Progressive Multiple Sclerosis: New Insights. *Neurology.* 2021 Aug 24;97(8):378-388. doi: 10.1212/WNL.0000000000012323. Epub 2021 Jun 4.
16. Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. *Lancet Neurol.* 2025 Oct;24(10):850-865. doi: 10.1016/S1474-4422(25)00270-4.

## Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management

NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime’s assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	No: PA not a priority
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

### Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
G35.A	Relapsing-remitting multiple sclerosis
G35.B0	Primary progressive multiple sclerosis, unspecified
G35.B1	Active primary progressive multiple sclerosis
G35.B2	Non-active primary progressive multiple sclerosis
G35.C0	Secondary progressive multiple sclerosis, unspecified
G35.C1	Active secondary progressive multiple sclerosis
G35.C2	Non-active secondary progressive multiple sclerosis
G35.D	Multiple sclerosis, unspecified

### Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC